Floatz logo

Chir-258

Non-Small Cell Lung Cancer

University of California, DavisPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
59/ 100

Competitive context

176 Active assets in the Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Anamorelin
Helsinn Healthcare SA
Phase 3BB
Atezolizumab
National Cancer Institute (NCI)
Phase 4BB
Docetaxel
Genfleet Therapeutics (Shanghai) Inc.
Phase 4BB
ETOPOSIDE
Pfizer
Phase 3BB
ALECTINIB
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase 4BB

View all 50 →

Same molecule, other indications

Chir-258 is also rated in:

NeoplasmsDormant
B
Indicative ·
57 / 100
View asset →
Stage III Pancreatic CancerDormant
CCC
Indicative ·
54 / 100
View asset →
Breast CancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →